AbbVie Terminates Alzheimer’s Pact With Voyager Therapeutics

Two years after AbbVie and Voyager Therapeutics first forged a collaboration to develop treatments for Alzheimer’s disease, the partnership has come to an end after AbbVie terminated the agreement. Voyager announced the two companies terminated their tau and alpha-synuclein vectorized antibody collaborations effective August 3, 2020.

In its announcement, Voyager did not specify the reasons for the termination of the collaboration with AbbVie. By terminating the agreement, AbbVie is free of some of the conditional payments the company would have had to provide if the research had moved into the clinical phase of testing. With the termination of . . .